Park Medi World Limited (PARKHOSPS) Financial Results — Revenue ₹1,679 Cr

StockFin.ai Try Free →

Investor Takeaways

Revenue of ₹1,679 crores reported for FY'26, matching prior year's revenue figure of ₹1,679 crores

Net profit of ₹274 crores recorded for FY'26, consistent with FY'25 profit of ₹274 crores

EBITDA margin expanded to 26% from 26% in FY'25

Bed capacity increased to 3,610 operational beds

ARPOB rose 7% YoY to ₹28,000

Receivables provision stood at ₹200 crores

Capex of ₹500 crores planned for expansion

Overall Tone: Neutral

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹1,679 Cr	N/A
Net Profit	₹274 Cr	N/A
EBITDA Margin	26%	N/A
EPS	Not available
OPM	Not available

What Changed

Park Medi World Limited reported FY'26 financial results showing revenue of ₹1,679 crores and net profit of ₹274 crores, both unchanged from FY'25 figures of ₹1,679 crores revenue and ₹274 crores profit. EBITDA margin remained stable at 26% compared to 26% in the prior year. The company expanded bed capacity to 3,610 operational beds during the fiscal year. ARPOB increased 7% YoY to ₹28,000, driven by favorable mix improvements. Receivables provision was maintained at ₹200 crores. Capex of ₹500 crores is planned over two years for greenfield expansion, targeting break-even within 12-15 months per bed. The company aims for a 70:30 government-to-private insurance mix by year-end and projects FY'27 revenue growth of 5-6% from CGHS rate hikes.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Park Medi World Limited	Not available	Not available	Not available	10,787.47
Sun Pharmaceutical Industries Limited	40.61	15.11%	20.34%	4,43,373.11
Divi's Laboratories Limited	71.87	16.56%	22.09%	1,78,142.69
Torrent Pharmaceuticals Limited	79.61	N/A	N/A	1,48,266.18

The company's valuation metrics are not directly comparable to peers due to missing P/E, ROE, and ROCE data in the provided fundamentals.

Risks & Concerns

Receivables provision of ₹200 crores may impact cash flow if collection delays occur

Capex of ₹500 crores requires successful execution to achieve target bed capacity of 5,460 by FY'28

ARPOB growth of 7% depends on sustained mix improvement and pricing power

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q3 FY'26	354	Not available	Not available
Q4 FY'26	460	Not available	Not available

📄 View Original Announcement (PDF)

📊 Stock Analysis — PARKHOSPS ✨ Ask AI About This

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Park Medi World Limited (PARKHOSPS) — Financial Results Announcement